Clinical Trials Browser

Recruiting × Pathologic Complete Response × 90 days × Clear all

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

Phase 2 Recruiting

35 enrolled

Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT06130995 2026-03-05

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Phase 1 Recruiting

46 enrolled

Pathologic Complete Response, Neoplasm, Residual

NCT04055220 2026-02-17

REGOSTA

Phase NA Recruiting

168 enrolled

Sarcoma

Pathologic Complete Response, Bone Neoplasms, Chondrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Patient Compliance, Sarcoma, Ewing, Osteosarcoma, Histiocytoma, Malignant Fibrous

NCT07353723 2026-01-20

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

Phase 2 Recruiting

10 enrolled

Head & Neck

Pathologic Complete Response, Head and Neck Neoplasms

NCT07353840 2026-01-20

T-START-CR

Recruiting

160 enrolled

Lymphoid

Pathologic Complete Response, Lymphoma, T-Cell, Peripheral

Clinical Trials

I-SPY

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

REGOSTA

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

T-START-CR